Lipoprotein(a) in coronary heart disease: Clinical significance and therapeutic options;Lipoprotein(a): Koronare herzerkrankung - Klinische bedeutung und therapieoptionen

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 44, 2005, Pages 2518-2523

  Leischik, Roman ^a,b   Dworrak, B ^a   Gulker H ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CARNITINE; ESTROGEN; FIBRIC ACID DERIVATIVE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; SIMVASTATIN; STATINE;

APHERESIS; ARTERIOSCLEROSIS; DRUG EFFECT; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT;

EID: 27844607684     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-918598     Document Type: Review

References (54)

1. Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clin Cardiol 2002; 25: 287-290
2. Akaike M, Azuma H, Kagawa A et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002; 48: 1454-1459
3. Angelin B. Therapy of lowering lipoprotein(a) levels. Curr Opin Lipidol 1997; 8: 337-341
4. Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989; 19: 235-240
5. Bambauer R, Schiel R, Latza R. Low-density Lipoprotein Apheresis: An Overview. Therap Apher Dial 2003; 7: 382-390
6. Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M. Lipoprotein(a) in the arterial wall. Eur Heart J 1990; 11: 174-183(Suppl E
7. Berg K. A new serum type system in man: the LP system. Acta Pathol Microbio Scand 1963; 59: 369-382
8. Boerwinkle E. Genetics of plasma lipoprotein(a) concentrations. Curr Opin Lipidol 1992; 3: 128-136
9. Bosch T, Keller C. Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction. Therap Apher Dial 2003; 7: 341-344
10. Cantin V, Gagnon F, Moorjani S et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-525
11. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-176
12. Cremer P, Nagel D, Mann H et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129: 221-230
13. rd crouse JR 3rd. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996; 7: 321-326
14. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-765
15. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085
16. Dangas G, Mehran R, Harpel PC et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-2042
17. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000; 85: 350-353
18. Espeland MA Marcovina SM, Miller V et al. for the PEPI investigators. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998; 97: 979-986
19. Evans RW, Shpilber O, Shaten BJ, Ali S, Kamboh I, Kuller L. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. J Clin Epidemiol 2001; 54: 51-57
20. Executive summary of the third report of the national cholesterol education programm (NECP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497
21. Frank S, Gauster M, Strauss J, Hrzenjak A, Kostner GM. Adenovirus mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo. Gene Therapy 2001 ; 8: 425-430
22. Ginsberg HN, Kris-Etherton P, Dennis B et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998; 18: 441-449
23. Gonbert S, Malinsky S, Sposito AC et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002; 164: 305-311
24. Grainger DJ, Kirschenlohr HL, Mecalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-1658
25. Harpel PC, Chang VT, Borth V. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89:10& hairsp; 193-10197
26. Hervio L, Chapman JM, Thillet J, Loyau S, Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993; 82: 392-397
27. Jauhiainen M, Koskinen P, Ehnholm et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67
28. Jenkins DJ, Kendall CW, Marchie A et al. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation 2002; 106: 1327-1332
29. Kiortsis DN, Tzotas T, Giral P et al. Changes in lipoprotein(a) levels and hormonal correlation during weight reduction program. Nutr Metab Cardiovasc Dis 2001 ; 11: 153-157
30. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004; 15: 167-174
31. Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study (editorial). Circulation 1999; 100: 1154-1160
32. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a)-phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow up. J Am Soc Nephrol 1999; 10: 1027-1036
33. Loscalzo J, Weinhold M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding and plasminogen activation. Arteriosclerosis 1990; 10: 240-245
34. Luc G, Bard JM, Arveiler D et al on behalf of the PRIME study group. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163: 377-384
35. Marcovina SM, Koschinsky ML Lipoprotein(a) concentration and apolipoprotein(a) size - a synergistic role in advanced atherosclerosis? Circulation 1999; 100: 1151-1153
36. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions. Clin Chem 2003; 49: 1785-1796
37. McLean JW, Tomlinson JE, Kuang WJ et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 300: 132-137
38. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-303
39. Miwa K, Nakagawa K, Yoshida N, Taguchi Y, Inoue H. Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm. J Amer Coll Cardiol 2000; 35: 1200-1205
40. Nomura S, Yamamura T, Yamamoto A et al. The association between lipoprotein(a) and severity of coronary and cerebrovascular atherosclerosis, especially in non-hypercholesterolemic subjects. Cardiovasc Risk Fact 1993; 3: 336-343
41. Nowak-Göttl U, Junker F, Hartmeier M et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-748
42. Phillips B, Ball C, Sackett D et al. Levels of evidence and grades of recommendation. Oxford: Oxford-Centre for Evidence Based Medicine, 2001
43. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-1452
44. Pokrovsky SN, Sussekov A, Afanasieva OI, Adamova IY, Lyakishev AA, Kukharchuk W. Extracorporal immunadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data. Chem Phys Lipids 1994; 67/68: 323-330
45. Scanu AM. Lipoprotein(a) and the atherothrombotic process: Mechanistics insights and clinical implications. Curr Atheroscler Rep 2003; 5: 106-113
46. Schuff-Werner P, Gohlke H, Bartmann U et al. and the HELP study group. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 1994; 24: 724-732
47. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-1499
48. Shewmon DA, Stock JL, Rosen CJ et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arteriosder Thromb 1994; 14: 1586-1593
49. Sirtori CR, Calabresi L, Ferrara S et al. L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000; 10: 247-251
50. Terres W, Tatsis E, Pfalzer B, Beil FU, Beilsiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91: 948-950
51. Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345: 811-816
52. Ullrich H, Lackner KJ, Schmitz G. Lipoprotein(a) apheresis in severe coronary heart disease: an immunadsorption method. Artif Org 1998; 22: 135-139
53. Von Depka M, Nowak-Göttl U, Eisert R et al. Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-3368
54. Von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-439